News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
|
Followers
|
13
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
405
|
|
Created
|
10/22/04
|
Type
|
Free
|
| Moderators | |||
Level 2 View - Not Realtime!
Q. What is swine flu?
A. Swine influenza, or flu, is a contagious respiratory disease that affects pigs. It is caused by a type-A influenza virus. Outbreaks in pigs occur year-round.
The most common version is H1N1. The current strain is a new variation of an H1N1 virus, which is a mix of human and animal versions.
EMFP .49...this is damn important for EMFP...Itochu is an $85 BILLION Corp-worldwide...they will sell at least thru out Asia...not just Japan...as bird flu is becoming a very real threat over there. This is part 1...part 2 are the results of the military testing due soon...see next PR below this one...the testing is just pro forma IMO...this will be a helluva one two punch and should finally get EMFP moving:
B: Itochu Techno Chemical Obtains Regulatory Approval to Import and Sell Emergen
y Filtration Products' Respiratory Devices in Japan
HENDERSON, Nev., Oct 21, 2004 (BUSINESS WIRE) -- Emergency Filtration Products
Inc. (EFP) (OTCBB: EMFP) today announced that its partner, Itochu Techno
Chemical Inc., has obtained a Certificate of Import and a Certificate of Sale
from Koseisho (the Japanese Ministry of Health and Welfare, akin to the U.S.
FDA) to immediately begin importing and selling EFP's RespAide, Vapor Isolation
Valve and Series One Breathing Circuit Filter products in Japan.
EFP and Itochu Techno Chemical have been collaborating for over 18 months in
order to help bring EFP's products to market in Japan, as well as preparing a
feasibility study to expand distribution to other Asian countries, with possible
global expansion. After filing an application with Koseisho on Feb. 27, 2004,
the two companies began working on a distribution agreement that would govern
the sale of EFP products to Itochu Techno Chemical and other related companies.
EFP expects to enter into a long-term distribution agreement in the near future.
"We are extremely pleased to have our products cleared for launch in Japan,"
said Douglas K. Beplate, president, EFP. "We would like to thank our partners at
Itochu Techno Chemical for all of their hard work with regard to the application
made with Koseisho and especially with respect to their meticulous and
painstaking approach to assuring the success of our products in the Japanese
market place." Beplate went on to add, "EFP is highly confident that Itochu
Techno Chemical's expertise will not only pay off in the rapidly growing $300
million Japanese market for respiratory products, but will also lead to success
in other Asian countries and beyond."
Itochu Techno Chemical (http://www.techno-chemical.com/ is a subsidiary of
Itochu Corp.
Itochu Corp. (http://www.itochu.co.jp/main/index.html), one of the world's
largest trading companies with 2003 revenues in excess of $85 billion, ranked
11th in the world by revenues, according to Forbes magazine. Itochu is a
globally integrated corporation with offices in over 80 countries and operations
that cover a broad spectrum of industries.
About Emergency Filtration Products Inc.
EFP (http://www.emergencyfiltration.com/) is an air filtration products
manufacturer whose patented 2H Technology(TM) filter system has produced
filtration efficiencies of "greater than 99.99%" at a particulate size of 0.027
microns. Its initial products were developed for the medical market: the Vapor
Isolation Valve(TM) and RespAide(R) CPR Isolation Mask used for resuscitation of
respiratory/cardiac arrest cases; and the 2H Breathing Circuit Filter for
ventilators, respirators and anesthesia circuitry. Each has received FDA
approval. The company also markets an Automated External Defibrillator Prep Kit
featuring RespAide; and the NanoMask(R), a nanotechnology enhanced environmental
mask. In addition to filtration products, the company supplies Superstat(R), a
modified hemostatic collagen, to the U.S. military for surgery and extreme wound
care.
B: Center for Commercialization of Advanced Technology -- CCAT --
B: Center for Commercialization of Advanced Technology -- CCAT -- Awards Emergen
HENDERSON, Nev., Sep 14, 2004 (BUSINESS WIRE) -- Emergency Filtration Products,
Inc. (EFP) (OTCBB:EMFP) announces that it has been awarded a Prototype
Development/Testing/Evaluation Grant (PDT&E) to develop a testing protocol for
filter media on behalf of the U.S. Military. As part of this project, EFP will
begin testing its licensed nano-enhanced filter media at Edgewood Chemical
Biological Center in Edgewood, Maryland within the next few weeks. The testing
and evaluation process is expected to take approximately one month to complete,
following which (assuming positive testing results), EFP expects to sub-license
its nano-enhanced filter media to a Department of Defense approved manufacturer
to enhance existing filtration products that are currently used by the U.S. Air
Force, Army and Navy, as well as to commence development of new product
applications that will serve to better protect U.S. Military personnel.
"The award of the PDT&E grant from CCAT to develop a standard filter media
testing protocol for the U.S. Military is a milestone for our company," said
Douglas K. Beplate, President, EFP. "While we originally expected to begin
testing for the U.S. Air Force last month, we have been requested to have our
filter technology tested for all branches of the Military simultaneously." Mr.
Beplate went on to add, "We expect that the testing will not only prove to be
successful, but will also lead to a rapid commercialization of our licensed
nano-enhanced filter media technology which will assist all branches of the U.S.
Military - Army, Air Force and Navy - to incorporate our technology into
applications that will serve the U.S. Military worldwide."
For the past 18 months, EFP has been working in conjunction with U.S. Army
Research, Development & Engineering Command (RDECOM) to test its nano-enhanced
2H filter technology in order to accelerate the commercial development of a
number of filter technology applications and allow for rapid procurement by the
U.S. Department of Defense. RDECOM has been examining how to apply the company's
filter technology to a large number of potential applications, including, but
not limited to: biohazard masks, transportation (aircraft, tanks, armored
personnel carriers) and buildings (military, industrial, office and
residential). The program has conducted a number of cost and user needs
analyses, economic analyses and technical viability studies of EFP's proprietary
licensed 2H Filter technology. Over 1,000 potential applications of EFP's filter
technology have been identified by RDECOM.
About RDECOM:
http://www.rdecom.army.mil/index.html
MISSION -- Get the right integrated technologies into the hands of warfighters
quicker.
VISION -- To be recognized as the preeminent world leader in research,
development and engineering of systems, whose hallmark is transitioning the
right technology in the shortest time to our Soldiers.
INTENT -- The Commanding General of the U.S. Army Materiel Command (AMC)
established the U.S. Army Research, Development & Engineering Command (RDECOM),
as a new major subordinate command within AMC. This new command will restructure
core in-house capabilities now so we can fully exploit the enormous potential
that resides in research activities around the world. RDECOM will respond
rapidly by integrating, maturing and demonstrating emerging technologies to
field the right equipment, in the shortest time, for our Soldiers.
About ECBC:
http://www.ecbc.army.mil/
ECBC is the nation's principal research and development center for chemical and
biological defense. Tracing its roots back to 1917, ECBC leverages more than 85
years of experience with live agent to develop and enhance defense systems.
ECBC seeks opportunities to develop partnerships with industry, academia and
state and local governments to continue achieving major technological advances
for national defense, civilian protection and industrial competitiveness.
Complimenting these efforts, the Center offers several unique facilities that
provide full life-cycle support to chemical and biological protection, detection
and monitoring capabilities.
About CCAT:
The CCAT (http://www.ccatsandiego.org/index.shtml)- supported by Congress and
funded by the Department of Defense - is a public-private collaborative
partnership between academia, industry, and government. Partners include San
Diego State University (SDSU) Foundation and Entrepreneurial Management Center,
the University of California, San Diego (UCSD) Jacobs School and UCSD CONNECT,
and Lockheed Martin ORINCON Technologies, Inc. with support from the Space and
Naval Warfare Systems Center, San Diego. The consortium-style CCAT intends to
bridge the gap that exists between the generators of technology, the Department
of Defense and the commercial marketplace. EFP will also be working in
conjunction with the Office of Technology Transfer and Commercialization (OTTC)
at California State University, San Bernardino (http://ottc.csusb.edu/), a CCAT
partner on this project.
